RECRUITING

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.

Official Title

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Quick Facts

Study Start:2024-02-16
Study Completion:2028-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06244485

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
9089926400
CTRinfo@dsi.com

Principal Investigator

Global Clinical Leader
STUDY_DIRECTOR
Daiichi Sankyo

Study Locations (Sites)

City of Hope At Orange County Lennar Foundation Cancer Center
Irvine, California, 92618
United States
Valkyrie Clinical Trials
Los Angeles, California, 90067
United States
Sharp Memorial Hospital
San Diego, California, 92123
United States
Brcr Medical Center, Inc Dba Boca Raton Clinical Research
Plantation, Florida, 33322
United States
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, Florida, 33612
United States
University of Hawaii At Manoa
Honolulu, Hawaii, 96813
United States
University of Chicago Medical Center
Chicago, Illinois, 60637
United States
Dana-Farber Cancer Institute - Parent.
Boston, Massachusetts, 02215
United States
Memorial Sloan-Kettering Cancer Center (Mskcc) - New York
New York, New York, 10065
United States
Clinical Research Alliance
Westbury, New York, 11590
United States
Unc Hospitals
Chapel Hill, North Carolina, 27514
United States
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
Providence Portland Medical Center
Portland, Oregon, 97213
United States
Mary Crowley Cancer Research Centers
Dallas, Texas, 75230
United States
University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030
United States
Next Virginia
Fairfax, Virginia, 22031
United States
Inova Schar Cancer Institute
Falls Church, Virginia, 22042
United States
Fred Hutch
Seattle, Washington, 98109
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Daiichi Sankyo

  • Global Clinical Leader, STUDY_DIRECTOR, Daiichi Sankyo

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-16
Study Completion Date2028-11-01

Study Record Updates

Study Start Date2024-02-16
Study Completion Date2028-11-01

Terms related to this study

Keywords Provided by Researchers

  • Advanced Solid Tumor
  • Valemetostat tosylate
  • DXD Antibody-drug Conjugates

Additional Relevant MeSH Terms

  • Advanced Solid Tumor